1.Signal transduction for cancer development. We are focusing on the signaling adaptor protein CRK. We have isolated human c-CRK and also its target molecules such as C3G and DOCK180, which are activators for small G proteins. CRK transmits signals from tyrosine kinases to small G proteins. CRK has been demonstrated to be an essential molecule for the malignant potential of various human cancers and thus should be a therapeutic target. Recently, we demonstrated the 3D structure of CRK, and based on the structure, the CRK signal inhibitor for cancer cell invasion is expected to be generated.
2.Bain tumor and neuropathology. To uncover the molecular mechanism of brain tumors and discover the new therapeutic reagents, we are trying to establish human glioblastoma models which are completely identical to the patient's original tumors. Brain tumor stem cells with CD133 positivity are also analyzed. For the treatment of glioblastoma by temozolomide, we have proposed a new approach for the evaluation of the MGMT status.
3.Clinical and translational pathology. Methodologically, microscopy-based time-lapse analysis with FRET, FISH, IHC, and immunoelectron microscopy are strong diagnostic and research tools in our lab. The following ongoing projects are of clinical significance: (i) Synovial sarcoma and SYT-SSX. (ii) Colon cancer and Cox-2. (iii) Respiratory system diseases including mesothelioma and pulmonary fibrosis. (iv) Hematopoietic cell specific DOCK2 research. (v) We accepted the evaluation of JC virus infection and the diagnosis for PML (progressive multifocal leukoencephalopathy) as a consultation.
1.For medical students. We are presenting the classes for Pathology, Pathology practice, and Pathophysiology.
2.For Graduate course students. We are presenting the classes for Pathology, and tumor pathology.
3.For pathology residents. We are involved in the education of autopsy and surgical pathology diagnosis, and also clinico-pathological conference (CPC).
Department of Translational Pathology
Shinya Tanaka, Cell Communication and Signaling
Shinya Tanaka, Japanese Journal of Clinical Oncology
We have collaborated with Dr. William W. Hall (College of Dublin, Irland), Dr. Stephan M. Feller (Oxford Univ., UK), Raymond Birge (New Jersey Medical Center, USA), and Dr. Marc Ladanyi (Memorial Sloan-Kettering Cancer Center, USA).
Copyright © Hokkaido University Graduate School of Medicine / School of Medicine.